Compare RWT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | ORIC |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.8M | 783.0M |
| IPO Year | 1995 | 2020 |
| Metric | RWT | ORIC |
|---|---|---|
| Price | $5.51 | $8.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $7.00 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 02-12-2026 | 02-17-2026 |
| Dividend Yield | ★ 12.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,897,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.68 | $3.90 |
| 52 Week High | $6.73 | $14.93 |
| Indicator | RWT | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 27.93 |
| Support Level | $5.49 | $7.84 |
| Resistance Level | $5.69 | $8.33 |
| Average True Range (ATR) | 0.13 | 0.43 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 25.71 | 18.04 |
Redwood Trust Inc is a real estate investment trust focused on different areas of housing credit. The company operates in three segments: Sequoia Mortgage Banking includes mortgage loan conduit that acquires residential consumer loans from third-party originators for sale to whole loan buyers and securitization; CoreVest Mortgage Banking segment includes consists of a platform that originates residential investor loans for securitization, sale, or transfer into Redwood Investments portfolio; and Redwood Investments segment consists of organic investments sourced through mortgage banking operations, including securities retained from Sequoia and CoreVest securitization activities. It derives maximum revenue from Redwood Investments segment.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.